Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes

Frontiers in Aging Neuroscience

Volumn 6, Issue SEP, 2014, Pages

  Miners, J Scott ^a   Palmer, Jennifer C ^a   Tayler, Hannah ^a   Palmer, Laura E ^a   Ashby, Emma ^a   Kehoe, Patrick G ^a   Love, Seth ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Alzheimer's disease; Angiotensin converting enzyme; Cerebral amyloid angiopathy; Cerebral hypoperfusion; Endothelin 1; Neprilysin

Indexed keywords

ANTIOXIDANT; NEUROPROTECTIVE AGENT; RESVERATROL; TRANSCRIPTION FACTOR NRF2;

ALZHEIMER DISEASE; ANTIAMYLOIDOGENIC ACTIVITY; ANTIOXIDANT ACTIVITY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SOLUBILITY; HUMAN; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; REVIEW; THERAPY EFFECT; WINE;

EID: 84907160225     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00238     Document Type: Review

References (226)

1. Acker, T., and Acker, H. (2004). Cellular oxygen sensing need in CNS function: physiological and pathological implications. J. Exp. Biol. 207, 3171-3188. doi: 10.1242/jeb.01075
2. Akiyama, H., Kondo, H., Ikeda, K., Kato, M., and McGeer, P. L. (2001). Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid β-protein (Aβ) deposition. Brain Res. 902, 277-281. doi: 10.1016/S0006-8993(01)02390-3
3. An, S. J., Boyd, R., Wang, Y., Qiu, X., and Wang, H. D. (2006). Endothelin-1 expression in vascular adventitial fibroblasts. Am. J. Physiol. Heart Circ. Physiol. 290, H700-H708. doi: 10.1152/ajpheart.00326.2005
4. An, S. J., Boyd, R., Zhu, M., Chapman, A., Pimentel, D. R., and Wang, H. D. (2007). NADPH oxidase mediates angiotensin II-induced endothelin-1 expression in vascular adventitial fibroblasts. Cardiovasc. Res. 75, 702-709. doi: 10.1016/j.cardiores.2007.02.015
5. Ao, Q., Hao, C., Xiong, M., and Wang, D. (2002). Expression of hypoxia-inducible factor-1 α and endothelin-1 gene in hypoxic pulmonary hypertension. Zhonghua Bing Li Xue Za Zhi 31, 140-142.
6. Arregui, A., Perry, E. K., Rossor, M., and Tomlinson, B. E. (1982). Angiotensin converting enzyme in Alzheimer's disease increased activity in caudate nucleus and cortical areas. J. Neurochem. 38, 1490-1492. doi: 10.1111/j.1471-4159.1982.tb07930.x
7. Ashby, E. L., and Kehoe, P. G. (2013). Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease. Expert Opin. Investig. Drugs 22, 1229-1242. doi: 10.1517/13543784.2013.812631
8. Baig, S., Kehoe, P. G., and Love, S. (2008). MMP-2, -3 and -9 levels and activity are not related to Aβ load in the frontal cortex in Alzheimer's disease. Neuropathol. Appl. Neurobiol. 34, 205-215. doi: 10.1111/j.1365-2990.2007.00897.x
9. Balakrishnan, S. M., Wang, H. D., Gopalakrishnan, V., Wilson, T. W., and McNeill, J. R. (1996). Effect of an endothelin antagonist on hemodynamic responses to angiotensin II. Hypertension 28, 806-809. doi: 10.1161/01.HYP.28.5.806
10. Ballard, C., O'Brien, J., Barber, B., Scheltens, P., Shaw, F., McKeith, I., et al. (2000). Neurocardiovascular instability, hypotensive episodes, and MRI lesions in neurodegenerative dementia. Ann. N.Y. Acad. Sci. 903, 442-445. doi: 10.1111/j.1749-6632.2000.tb06396.x
11. Ballard, C. G., O'Brien, J., Lowery, K., Ayre, G. A., Harrison, R., Perry, R., et al. (1998). A prospective study of dementia with Lewy bodies. Age Ageing 27, 631-636. doi: 10.1093/ageing/27.5.631
12. Barker, R., Ashby, E. L., Wellington, D., Barrow, V. M., Palmer, J. C., Kehoe, P. G., et al. (2014). Pathophysiology of white matter perfusion in Alzheimer's disease and vascular dementia. Brain 137, 1524-1532. doi: 10.1093/brain/awu040
13. Barker, R., Love, S., and Kehoe, P. G. (2010). Plasminogen and plasmin in Alzheimer's disease. Brain Res. 1355, 7-15. doi: 10.1016/j.brainres.2010.08.025
14. Barker, R., Wellington, D., Esiri, M. M., and Love, S. (2013). Assessing white matter ischemic damage in dementia patients by measurement of myelin proteins. J. Cereb. Blood Flow Metab. 33, 1050-1057. doi: 10.1038/jcbfm.2013.46
15. Barnes, J. M., Barnes, N. M., Costall, B., Coughlan, J., Kelly, M. E., Naylor, R. J., et al. (1992). Angiotensin-converting enzyme inhibition, angiotensin, and cognition. J. Cardiovasc. Pharmacol. 19(Suppl. 6), S63-S71. doi: 10.1097/00005344-199219006-00011
16. Barnes, N. M., Cheng, C. H., Costall, B., Naylor, R. J., Williams, T. J., and Wischik, C. M. (1991). Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Eur. J. Pharmacol. 200, 289-292. doi: 10.1016/0014-2999(91)90584-D
17. Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., and Holtzman, D. M. (2006). Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12, 856-861. doi: 10.1038/nm1438
18. Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., et al. (2007). Transport pathways for clearance of human Alzheimer's amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 27, 909-918. doi: 10.1038/sj.jcbfm.9600419
19. Belza, M. G., and Urich, H. (1986). Cerebral amyloid angiopathy in Down's syndrome. Clin. Neuropathol. 5, 257-260.
20. Borges, R., Von Grafenstein, H., and Knight, D. E. (1989). Tissue selectivity of endothelin. Eur. J. Pharmacol. 165, 223-230. doi: 10.1016/0014-2999(89)90716-4
21. Brain, S. D. (1989). The direct observation of arteriolar constriction induced by endothelin in vivo. Eur. J. Pharmacol. 160, 401-403. doi: 10.1016/0014-2999(89)90096-4
22. Brain, S. D., Tippins, J. R., and Williams, T. J. (1988). Endothelin induces potent microvascular constriction. Br. J. Pharmacol. 95, 1005-1007. doi: 10.1111/j.1476-5381.1988.tb11731.x
23. Briyal, S., Philip, T., and Gulati, A. (2011). Endothelin-A receptor antagonists prevent amyloid-β-induced increase in ETA receptor expression, oxidative stress, and cognitive impairment. J. Alzheimers Dis. 23, 491-503. doi: 10.3233/JAD-2010-101245
24. Briyal, S., Shepard, C., and Gulati, A. (2014). Endothelin receptor type B agonist, IRL-1620, prevents β amyloid (Aβ) induced oxidative stress and cognitive impairment in normal and diabetic rats. Pharmacol. Biochem. Behav. 120, 65-72. doi: 10.1016/j.pbb.2014.02.008
25. Brun, A., and Englund, E. (1986a). Brain changes in dementia of Alzheimer's type relevant to new imaging diagnostic methods. Prog. Neuropsychopharmacol. Biol. Psychiatry 10, 297-308. doi: 10.1016/0278-5846(86)90009-6
26. Brun, A., and Englund, E. (1986b). A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann. Neurol. 19, 253-262. doi: 10.1002/ana.410190306
27. Bruno, M. A., Mufson, E. J., Wuu, J., and Cuello, A. C. (2009). Increased matrix metalloproteinase 9 activity in mild cognitive impairment. J. Neuropathol. Exp. Neurol. 68, 1309-1318. doi: 10.1097/NEN.0b013e3181c22569
28. Burgermeister, P., Calhoun, M. E., Winkler, D. T., and Jucker, M. (2000). Mechanisms of cerebrovascular amyloid deposition. Lessons from mouse models. Ann. N.Y. Acad. Sci. 903, 307-316. doi: 10.1111/j.1749-6632.2000.tb06381.x
29. Cabrejo, L., Guyant-Marechal, L., Laquerriere, A., Vercelletto, M., De la Fourniere, F., Thomas-Anterion, C., et al. (2006). Phenotype associated with APP duplication in five families. Brain 129, 2966-2976. doi: 10.1093/brain/awl237
30. Calhoun, M. E., Burgermeister, P., Phinney, A. L., Stalder, M., Tolnay, M., Wiederhold, K. H., et al. (1999). Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc. Natl. Acad. Sci. U.S.A. 96, 14088-14093. doi: 10.1073/pnas.96.24.14088
31. Carpentier, M., Robitaille, Y., DesGroseillers, L., Boileau, G., and Marcinkiewicz, M. (2002). Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy. J. Neuropathol. Exp. Neurol. 61, 849-856.
32. Carson, J. A., and Turner, A. J. (2002). B-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J. Neurochem. 81, 1-8. doi: 10.1046/j.1471-4159.2002.00855.x
33. Chui, H. C., Zheng, L., Reed, B. R., Vinters, H. V., and Mack, W. J. (2012). Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review. Alzheimers Res. Ther. 4, 1. doi: 10.1186/alzrt98
34. Claassen, J. A., and Zhang, R. (2011). Cerebral autoregulation in Alzheimer's disease. J. Cereb. Blood Flow Metab. 31, 1572-1577. doi: 10.1038/jcbfm.2011.69
35. Colloby, S. J., Fenwick, J. D., Williams, E. D., Paling, S. M., Lobotesis, K., Ballard, C., et al. (2002). A comparison of (99m)Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping. Eur. J. Nucl. Med. Mol. Imaging 29, 615-622. doi: 10.1007/s00259-002-0778-5
36. Danielyan, L., Klein, R., Hanson, L. R., Buadze, M., Schwab, M., Gleiter, C. H., et al. (2010). Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res. 13, 195-201. doi: 10.1089/rej.2009.0944
37. Davies, N. M., Kehoe, P. G., Ben-Shlomo, Y., and Martin, R. M. (2011). Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J. Alzheimers Dis. 26, 699-708. doi: 10.3233/JAD-2011-110347
38. de la Torre, J. C. (2005). Is Alzheimer's disease preceded by neurodegeneration or cerebral hypoperfusion? Ann. Neurol. 57, 783-784. doi: 10.1002/ana.20516
39. Deb, S., Zhang, J. W., and Gottschall, P. E. (1999). Activated isoforms of MMP-2 are induced in U87 human glioma cells in response to β-amyloid peptide. J. Neurosci. Res. 55, 44-53.
40. DeKosky, S. T., Shih, W. J., Schmitt, F. A., Coupal, J., and Kirkpatrick, C. (1990). Assessing utility of single photon emission computed tomography (SPECT) scan in Alzheimer disease: correlation with cognitive severity. Alzheimer Dis. Assoc. Disord. 4, 14-23. doi: 10.1097/00002093-199040100-00002
41. Dickstein, D. L., Walsh, J., Brautigam, H., Stockton, S. D. Jr., Gandy, S., and Hof, P. R. (2010). Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt. Sinai J. Med. 77, 82-102. doi: 10.1002/msj.20155
42. Dohi, Y., Hahn, A. W., Boulanger, C. M., Buhler, F. R., and Luscher, T. F. (1992). Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 19, 131-137. doi: 10.1161/01.HYP.19.2.131
43. Donahue, J. E., Khurana, J. S., and Adelman, L. S. (1998). Intracerebral hemorrhage in two patients with Down's syndrome and cerebral amyloid angiopathy. Acta Neuropathol. 95, 213-216. doi: 10.1007/s004010050789
44. Eckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., et al. (2006). Regulation of steady-state β-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J. Biol. Chem. 281, 30471-30478. doi: 10.1074/jbc.M605827200
45. Eckman, E. A., and Eckman, C. B. (2005). Aβ-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem. Soc. Trans. 33, 1101-1105. doi: 10.1042/BST20051101
46. Eckman, E. A., Reed, D. K., and Eckman, C. B. (2001). Degradation of the Alzheimer's amyloid β peptide by endothelin-converting enzyme. J. Biol. Chem. 276, 24540-24548. doi: 10.1074/jbc.M007579200
47. Eckman, E. A., Watson, M., Marlow, L., Sambamurti, K., and Eckman, C. B. (2003). Alzheimer's disease β-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J. Biol. Chem. 278, 2081-2084. doi: 10.1074/jbc.C200642200
48. El-Amouri, S. S., Zhu, H., Yu, J., Marr, R., Verma, I. M., and Kindy, M. S. (2008). Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am. J. Pathol. 172, 1342-1354. doi: 10.2353/ajpath.2008.070620
49. Elkins, J. S., Douglas, V. C., and Johnston, S. C. (2004). Alzheimer disease risk and genetic variation in ACE: a meta-analysis. Neurology 62, 363-368. doi: 10.1212/01.WNL.0000106823.72493.FF
50. Ellis, R. J., Olichney, J. M., Thal, L. J., Mirra, S. S., Morris, J. C., Beekly, D., et al. (1996). Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 46, 1592-1596. doi: 10.1212/WNL.46.6.1592
51. Englund, E., and Brun, A. (1990). White matter changes in dementia of Alzheimer's type: the difference in vulnerability between cell compartments. Histopathology 16, 433-439. doi: 10.1111/j.1365-2559.1990.tb01542.x
52. Englund, E., Brun, A., and Alling, C. (1988). White matter changes in dementia of Alzheimer's type. Biochemical and neuropathological correlates. Brain 111(pt 6), 1425-39. doi: 10.1093/brain/111.6.1425
53. Esiri, M. M., and Wilcock, G. K. (1986). Cerebral amyloid angiopathy in dementia and old age. J. Neurol. Neurosurg. Psychiatr. 49, 1221-1226. doi: 10.1136/jnnp.49.11.1221
54. Evin, G., and Weidemann, A. (2002). Biogenesis and metabolism of Alzheimer's disease Aβ amyloid peptides. Peptides 23, 1285-1297. doi: 10.1016/S0196-9781(02)00063-3
55. Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., et al. (2003). Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U.S.A. 100, 4162-4167. doi: 10.1073/pnas.0230450100
56. Farris, W., Schutz, S. G., Cirrito, J. R., Shankar, G. M., Sun, X., George, A., et al. (2007). Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am. J. Pathol. 171, 241-251. doi: 10.2353/ajpath.2007.070105
57. Fernando, M. S., Simpson, J. E., Matthews, F., Brayne, C., Lewis, C. E., Barber, R., et al. (2006). White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke 37, 1391-1398. doi: 10.1161/01.STR.0000221308.94473.14
58. Firbank, M. J., Colloby, S. J., Burn, D. J., McKeith, I. G., and O'Brien, J. T. (2003). Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage 20, 1309-1319. doi: 10.1016/S1053-8119(03)00364-1
59. Fong, T. G., Inouye, S. K., Dai, W., Press, D. Z., and Alsop, D. C. (2011). Association cortex hypoperfusion in mild dementia with Lewy bodies: a potential indicator of cholinergic dysfunction? Brain Imaging Behav. 5, 25-35. doi: 10.1007/s11682-010-9108-x
60. Gan, L., Ye, S., Chu, A., Anton, K., Yi, S., Vincent, V. A., et al. (2004). Identification of cathepsin B as a mediator of neuronal death induced by Aβ-activated microglial cells using a functional genomics approach. J. Biol. Chem. 279, 5565-5572. doi: 10.1074/jbc.M306183200
61. Gao, Y., O'Caoimh, R., Healy, L., Kerins, D. M., Eustace, J., Guyatt, G., et al. (2013). Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open 3:e002881. doi: 10.1136/bmjopen-2013-002881
62. Garcia-Alloza, M., Gregory, J., Kuchibhotla, K. V., Fine, S., Wei, Y., Ayata, C., et al. (2011). Cerebrovascular lesions induce transient β-amyloid deposition. Brain 134, 3697-3707. doi: 10.1093/brain/awr300
63. Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L. Jr., Younkin, L. H., et al. (1995). Amyloid β protein (Aβ) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A β 40 or A β 42(43). J. Biol. Chem. 270, 7013-7016.
64. Guan, H., Liu, Y., Daily, A., Police, S., Kim, M. H., Oddo, S., et al. (2009). Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease. J. Neurosci. Res. 87, 1462-1473. doi: 10.1002/jnr.21944
65. Guglielmotto, M., Aragno, M., Autelli, R., Giliberto, L., Novo, E., Colombatto, S., et al. (2009). The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1α. J. Neurochem. 108, 1045-1056. doi: 10.1111/j.1471-4159.2008.05858.x
66. Hafez, D., Huang, J. Y., Huynh, A. M., Valtierra, S., Rockenstein, E., Bruno, A. M., et al. (2011). Neprilysin-2 is an important β-amyloid degrading enzyme. Am. J. Pathol. 178, 306-312. doi: 10.1016/j.ajpath.2010.11.012
67. Hamdi, H. K., and Castellon, R. (2004). A genetic variant of ACE increases cell survival: a new paradigm for biology and disease. Biochem. Biophys. Res. Commun. 318, 187-191. doi: 10.1016/j.bbrc.2004.04.004
68. Hardy, J. (1997). Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20, 154-159. doi: 10.1016/S0166-2236(96)01030-2
69. Hawkes, C. A., Hartig, W., Kacza, J., Schliebs, R., Weller, R. O., Nicoll, J. A., et al. (2011). Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol. 121, 431-443. doi: 10.1007/s00401-011-0801-7
70. Haynes, W. G., and Webb, D. J. (1994). Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344, 852-854. doi: 10.1016/S0140-6736(94)92827-4
71. He, M., Ohrui, T., Maruyama, M., Tomita, N., Nakayama, K., Higuchi, M., et al. (2006). ACE activity in CSF of patients with mild cognitive impairment and Alzheimer disease. Neurology 67, 1309-1310. doi: 10.1212/01.wnl.0000238102.04582.ec
72. Hellstrom-Lindahl, E., Ravid, R., and Nordberg, A. (2008). Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A β levels. Neurobiol. Aging 29, 210-221. doi: 10.1016/j.neurobiolaging.2006.10.010
73. Hemming, M. L., and Selkoe, D. J. (2005). Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J. Biol. Chem. 280, 37644-37650. doi: 10.1074/jbc.M508460200
74. Hemming, M. L., Selkoe, D. J., and Farris, W. (2007). Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease. Neurobiol. Dis. 26, 273-281. doi: 10.1016/j.nbd.2007.01.004
75. Henderson, S. J., Andersson, C., Narwal, R., Janson, J., Goldschmidt, T. J., Appelkvist, P., et al. (2014). Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β. Brain 137, 553-564. doi: 10.1093/brain/awt308
76. Hu, J., Igarashi, A., Kamata, M., and Nakagawa, H. (2001). Angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide (Aβ); retards A β aggregation, deposition, fibril formation; and inhibits cytotoxicity. J. Biol. Chem. 276, 47863-47868. doi: 10.1074/jbc.M104068200
77. Huang, S. M., Mouri, A., Kokubo, H., Nakajima, R., Suemoto, T., Higuchi, M., et al. (2006). Neprilysin-sensitive synapse-associated amyloid-β peptide oligomers impair neuronal plasticity and cognitive function. J. Biol. Chem. 281, 17941-17951. doi: 10.1074/jbc.M601372200
78. Hughes, P. M., Anthony, D. C., Ruddin, M., Botham, M. S., Rankine, E. L., Sablone, M., et al. (2003). Focal lesions in the rat central nervous system induced by endothelin-1. J. Neuropathol. Exp. Neurol. 62, 1276-1286.
79. Iadecola, C. (2003). Cerebrovascular effects of amyloid-β peptides: mechanisms and implications for Alzheimer's dementia. Cell. Mol. Neurobiol. 23, 681-689. doi: 10.1023/A:1025092617651
80. Iadecola, C. (2004). Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 5, 347-360. doi: 10.1038/nrn1387
81. Ishii, K., Yamaji, S., Kitagaki, H., Imamura, T., Hirono, N., and Mori, E. (1999). Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology 53, 413-416. doi: 10.1212/WNL.53.2.413
82. 1-42-degrading catabolic pathway in brain parenchyma]. Seikagaku 75, 97-107.
83. Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N. P., et al. (2001). Metabolic regulation of brain Aβ by neprilysin. Science 292, 1550-1552. doi: 10.1126/science.1059946
84. 1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6, 143-150. doi: 10.1038/77399
85. Jagust, W. J., Budinger, T. F., and Reed, B. R. (1987). The diagnosis of dementia with single photon emission computed tomography. Arch. Neurol. 44, 258-262. doi: 10.1001/archneur.1987.00520150014011
86. Jarrett, J. T., Berger, E. P., and Lansbury, P. T. Jr. (1993). The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693-4697. doi: 10.1021/bi00069a001
87. Jellinger, K. A., and Attems, J. (2006). Prevalence and impact of cerebrovascular pathology in Alzheimer's disease and parkinsonism. Acta Neurol. Scand. 114, 38-46. doi: 10.1111/j.1600-0404.2006.00665.x
88. Jochemsen, H. M., Geerlings, M. I., Grool, A. M., Vincken, K. L., Mali, W. P., van der Graaf, Y., et al. (2012b). Angiotensin-converting enzyme and progression of white matter lesions and brain atrophy-the SMART-MR study. J. Alzheimers Dis. 29, 39-49. doi: 10.3233/JAD-2012-111772
89. Jochemsen, H. M., Geerlings, M. I., Visseren, F. L., Algra, A., van der Graaf, Y., Muller, M., et al. (2012a). Serum angiotensin-converting enzyme and recurrent vascular events. The SMART-MR study. Atherosclerosis 224, 486-491. doi: 10.1016/j.atherosclerosis.2012.07.010
90. Johnson, N. A., Jahng, G. H., Weiner, M. W., Miller, B. L., Chui, H. C., Jagust, W. J., et al. (2005). Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 234, 851-859. doi: 10.1148/radiol.2343040197
91. Jung, S. S., Zhang, W., and Van Nostrand, W. E. (2003). Pathogenic A β induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascular smooth muscle cells. J. Neurochem. 85, 1208-1215. doi: 10.1046/j.1471-4159.2003.01745.x
92. Kalaria, R. N. (2000). The role of cerebral ischemia in Alzheimer's disease. Neurobiol. Aging 21, 321-330. doi: 10.1016/S0197-4580(00)00125-1
93. Kang, B. Y., Kleinhenz, J. M., Murphy, T. C., and Hart, C. M. (2011). The PPARγ ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo. Am. J. Physiol. Lung Cell. Mol. Physiol. 301, L881-L891. doi: 10.1152/ajplung.00195.2011
94. Kauwe, J. S., Wang, J., Mayo, K., Morris, J. C., Fagan, A. M., Holtzman, D. M., et al. (2009). Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid β. Neurogenetics 10, 13-17. doi: 10.1007/s10048-008-0150-4
95. Kawaguchi, H., Sawa, H., and Yasuda, H. (1991). Effect of endothelin on angiotensin converting enzyme activity in cultured pulmonary artery endothelial cells. J. Hypertens. 9, 171-174. doi: 10.1097/00004872-199102000-00012
96. Kehoe, P. G., Davies, N. M., Martin, R. M., and Ben-Shlomo, Y. (2013). Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia. J. Alzheimers Dis. 33, 999-1008. doi: 10.3233/JAD-2012-121090
97. Kehoe, P. G., Katzov, H., Feuk, L., Bennet, A. M., Johansson, B., Wiman, B., et al. (2003). Haplotypes extending across ACE are associated with Alzheimer's disease. Hum. Mol. Genet. 12, 859-867. doi: 10.1093/hmg/ddg094
98. Kehoe, P. G., Miners, S., and Love, S. (2009). Angiotensins in Alzheimer's disease - friend or foe? Trends Neurosci. 32, 619-628. doi: 10.1016/j.tins.2009.07.006
99. Kehoe, P. G., Russ, C., McIlory, S., Williams, H., Holmans, P., Holmes, C., et al. (1999). Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat. Genet. 21, 71-72. doi: 10.1038/5009
100. Kenny, R. A., Shaw, F. E., O'Brien, J. T., Scheltens, P. H., Kalaria, R., and Ballard, C. (2004). Carotid sinus syndrome is common in dementia with Lewy bodies and correlates with deep white matter lesions. J. Neurol. Neurosurg. Psychiatr. 75, 966-971. doi: 10.1136/jnnp.2003.023812
101. Krick, S., Hanze, J., Eul, B., Savai, R., Seay, U., Grimminger, F., et al. (2005). Hypoxia-driven proliferation of human pulmonary artery fibroblasts: cross-talk between HIF-1α and an autocrine angiotensin system. FASEB J. 19, 857-859. doi: 10.1096/fj.04-2890fje
102. Kuhnke, D., Jedlitschky, G., Grube, M., Krohn, M., Jucker, M., Mosyagin, I., et al. (2007). MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-β peptides-implications for the mechanisms of Aβ clearance at the blood-brain barrier. Brain Pathol. 17, 347-353. doi: 10.1111/j.1750-3639.2007.00075.x
103. Lam, F. C., Liu, R., Lu, P., Shapiro, A. B., Renoir, J. M., Sharom, F. J., et al. (2001). β-Amyloid efflux mediated by p-glycoprotein. J. Neurochem. 76, 1121-1128. doi: 10.1046/j.1471-4159.2001.00113.x
104. Leal, M. C., Dorfman, V. B., Gamba, A. F., Frangione, B., Wisniewski, T., Castano, E. M., et al. (2006). Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology. J. Neuropathol. Exp. Neurol. 65, 976-987. doi: 10.1097/01.jnen.0000235853.70092.ba
105. Lee, J. M., Yin, K. J., Hsin, I., Chen, S., Fryer, J. D., Holtzman, D. M., et al. (2003). Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy. Ann. Neurol. 54, 379-382. doi: 10.1002/ana.10671
106. Lehmann, D. J., Cortina-Borja, M., Warden, D. R., Smith, A. D., Sleegers, K., Prince, J. A., et al. (2005). Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am. J. Epidemiol. 162, 305-317. doi: 10.1093/aje/kwi202
107. Leissring, M. A., Farris, W., Chang, A. Y., Walsh, D. M., Wu, X., Sun, X., et al. (2003). Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087-1093. doi: 10.1016/S0896-6273(03)00787-6
108. Li, H., Chen, S. J., Chen, Y. F., Meng, Q. C., Durand, J., Oparil, S., et al. (1994). Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. J. Appl. Physiol. (1985) 77, 1451-1459.
109. Li, H., Wetten, S., Li, L., St Jean, P. L., Upmanyu, R., Surh, L., et al. (2008). Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch. Neurol. 65, 45-53. doi: 10.1001/archneurol.2007.3
110. Li, J., Wang, Y. J., Zhang, M., Fang, C. Q., and Zhou, H. D. (2011). Cerebral ischemia aggravates cognitive impairment in a rat model of Alzheimer's disease. Life Sci. 89, 86-92. doi: 10.1016/j.lfs.2011.04.024
111. Li, L., Zhang, X., Yang, D., Luo, G., Chen, S., and Le, W. (2009). Hypoxia increases Aβ generation by altering β- and γ-cleavage of APP. Neurobiol. Aging 30, 1091-1098. doi: 10.1016/j.neurobiolaging.2007.10.011
112. Li, M., Liu, Y., Jin, F., Sun, X., Li, Z., Liu, Y., et al. (2012). Endothelin-1 induces hypoxia inducible factor 1α expression in pulmonary artery smooth muscle cells. FEBS Lett. 586, 3888-3893. doi: 10.1016/j.febslet.2012.08.036
113. Li, N. C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E., et al. (2010). Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 340:b5465. doi: 10.1136/bmj.b5465
114. Liu, Y., Cox, S. R., Morita, T., and Kourembanas, S. (1995). Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ. Res. 77, 638-643. doi: 10.1161/01.RES.77.3.638
115. Liu, Y., Studzinski, C., Beckett, T., Guan, H., Hersh, M. A., Murphy, M. P., et al. (2009). Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol. Ther. 17, 1381-1386. doi: 10.1038/mt.2009.115
116. Lobotesis, K., Fenwick, J. D., Phipps, A., Ryman, A., Swann, A., Ballard, C., et al. (2001). Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 56, 643-649. doi: 10.1212/WNL.56.5.643
117. Love, S., Nicoll, J. A., Hughes, A., and Wilcock, G. K. (2003). APOE and cerebral amyloid angiopathy in the elderly. Neuroreport 14, 1535-1536. doi: 10.1097/00001756-200308060-00027
118. Luo, J., and Grammas, P. (2010). Endothelin-1 is elevated in Alzheimer's disease brain microvessels and is neuroprotective. J. Alzheimers Dis. 21, 887-896. doi: 10.3233/JAD-2010-091486
119. Lynch, J. A., George, A. M., Eisenhauer, P. B., Conn, K., Gao, W., Carreras, I., et al. (2006). Insulin degrading enzyme is localized predominantly at the cell surface of polarized and unpolarized human cerebrovascular endothelial cell cultures. J. Neurosci. Res. 83, 1262-1270. doi: 10.1002/jnr.20809
120. Maguire, J. J. (2002). Endothelin-converting enzyme activity in vascular smooth muscle preparations in vitro. Methods Mol. Biol. 206, 165-177. doi: 10.1385/1-59259-289-9:165
121. Mak, H. K., Chan, Q., Zhang, Z., Petersen, E. T., Qiu, D., Zhang, L., et al. (2012). Quantitative assessment of cerebral hemodynamic parameters by QUASAR arterial spin labeling in Alzheimer's disease and cognitively normal Elderly adults at 3-tesla. J. Alzheimers Dis. 31, 33-44. doi: 10.3233/JAD-2012-111877
122. Marr, R. A., Guan, H., Rockenstein, E., Kindy, M., Gage, F. H., Verma, I., et al. (2004). Neprilysin regulates amyloid B peptide levels. J. Mol. Neurosci. 22, 5-11. doi: 10.1385/JMN:22:1-2:5
123. Marr, R. A., Rockenstein, E., Mukherjee, A., Kindy, M. S., Hersh, L. B., Gage, F. H., et al. (2003). Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J. Neurosci. 23, 1992-1996.
124. Mattson, M. P. (2004). Pathways towards and away from Alzheimer's disease. Nature 430, 631-639. doi: 10.1038/nature02621
125. Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., et al. (2010). Decreased clearance of CNS β-amyloid in Alzheimer's disease. Science 330, 1774. doi: 10.1126/science.1197623
126. Miller, B. C., Eckman, E. A., Sambamurti, K., Dobbs, N., Chow, K. M., Eckman, C. B., et al. (2003). Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc. Natl. Acad. Sci. U.S.A. 100, 6221-6226. doi: 10.1073/pnas.1031520100
127. Minami, M., Kimura, M., Iwamoto, N., and Arai, H. (1995). Endothelin-1-like immunoreactivity in cerebral cortex of Alzheimer-type dementia. Prog. Neuropsychopharmacol. Biol. Psychiatry 19, 509-513. doi: 10.1016/0278-5846(95)00031-P
128. Miners, J. S., Ashby, E., Van Helmond, Z., Chalmers, K. A., Palmer, L. E., Love, S., et al. (2008c). Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol. Appl. Neurobiol. 34, 181-193. doi: 10.1111/j.1365-2990.2007.00885.x
129. Miners, J. S., Baig, S., Tayler, H., Kehoe, P. G., and Love, S. (2009). Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J. Neuropathol. Exp. Neurol. 68, 902-914. doi: 10.1097/NEN.0b013e3181afe475
130. Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., and Love, S. (2011a). Aβ-degrading enzymes: potential for treatment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 70, 944-959. doi: 10.1097/NEN.0b013e3182345e46
131. Miners, J. S., Kehoe, P., and Love, S. (2011c). Neprilysin protects against cerebral amyloid angiopathy and Aβ-induced degeneration of cerebrovascular smooth muscle cells. Brain Pathol. 21, 594-605. doi: 10.1111/j.1750-3639.2011.00486
132. Miners, J. S., Kehoe, P. G., and Love, S. (2008a). Immunocapture-based fluorometric assay for the measurement of insulin-degrading enzyme activity in brain tissue homogenates. J. Neurosci. Methods 169, 177-181. doi: 10.1016/j.jneumeth.2007.12.003
133. Miners, J. S., Morris, S., Love, S., and Kehoe, P. G. (2011b). Accumulation of insoluble amyloid-β in down's syndrome is associated with increased BACE-1 and neprilysin activities. J. Alzheimers Dis. 23, 101-108. doi: 10.3233/JAD-2010-101395
134. Miners, J. S., van Helmond, Z., Chalmers, K., Wilcock, G., Love, S., and Kehoe, P. G. (2006). Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J. Neuropathol. Exp. Neurol. 65, 1012-1021. doi: 10.1097/01.jnen.0000240463.87886.9a
135. Miners, J. S., van Helmond, Z., Kehoe, P. G., and Love, S.(2010a). Changes with age in the activities of β-secretase and the Aβ-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme. Brain Pathol. 20, 794-802. doi: 10.1111/j.1750-3639.2010.00375.x
136. Miners, J. S., van Helmond, Z., Raiker, M., Love, S., and Kehoe, P. G. (2010b). ACE variants and association with brain Aβ levels in Alzheimer's disease. Am. J. Transl. Res. 3, 73-80.
137. Miners, J. S., Verbeek, M. M., Rikkert, M. O., Kehoe, P. G., and Love, S. (2008b). Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. J. Neurosci. Methods 167, 229-236. doi: 10.1016/j.jneumeth.2007.08.012
138. Miners, S., Moulding, H., de Silva, R., and Love, S. (2014). Reduced vascular endothelial growth factor and capillary density in the occipital cortex in dementia with lewy bodies. Brain Pathol. 24, 334-343. doi: 10.1111/bpa.12130
139. Mohajeri, M. H., Kuehnle, K., Li, H., Poirier, R., Tracy, J., and Nitsch, R. M. (2004). Anti-amyloid activity of neprilysin in plaque-bearing mouse models of Alzheimer's disease. FEBS Lett. 562, 16-21. doi: 10.1016/S0014-5793(04)00169-3
140. Mohajeri, M. H., Wollmer, M. A., and Nitsch, R. M. (2002). Aβ 42-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo. J. Biol. Chem. 277, 35460-35465. doi: 10.1074/jbc.M202899200
141. Moreau, P., d'Uscio, L. V., Shaw, S., Takase, H., Barton, M., and Luscher, T. F. (1997). Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 96, 1593-1597. doi: 10.1161/01.CIR.96.5.1593
142. Morelli, L., Llovera, R. E., Mathov, I., Lue, L. F., Frangione, B., Ghiso, J., et al. (2004). Insulin-degrading enzyme in brain microvessels: proteolysis of amyloid β vasculotropic variants and reduced activity in cerebral amyloid angiopathy. J. Biol. Chem. 279, 56004-56013. doi: 10.1074/jbc.M407283200
143. Mortensen, L. H., Pawloski, C. M., Kanagy, N. L., and Fink, G. D. (1990). Chronic hypertension produced by infusion of endothelin in rats. Hypertension 15, 729-733. doi: 10.1161/01.HYP.15.6.729
144. Mueller-Steiner, S., Zhou, Y., Arai, H., Roberson, E. D., Sun, B., Chen, J., et al. (2006). Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 51, 703-714. doi: 10.1016/j.neuron.2006.07.027
145. Mukherjee, A., Song, E., Kihiko-Ehmann, M., Goodman, J. P. Jr., Pyrek, J. S., Estus, S., et al. (2000). Insulysin hydrolyzes amyloid β peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J. Neurosci. 20, 8745-8749.
146. Nalivaeva, N. N., Belyaev, N. D., Zhuravin, I. A., and Turner, A. J. (2012). The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it? Int. J. Alzheimers Dis. 2012, 383796. doi: 10.1155/2012/383796
147. Nanduri, J., Yuan, G., Kumar, G. K., Semenza, G. L., and Prabhakar, N. R. (2008). Transcriptional responses to intermittent hypoxia. Respir. Physiol. Neurobiol. 164, 277-281. doi: 10.1016/j.resp.2008.07.006
148. Narain, Y., Yip, A., Murphy, T., Brayne, C., Easton, D., Evans, J. G., et al. (2000). The ACE gene and Alzheimer's disease susceptibility. J. Med. Genet. 37, 695-697. doi: 10.1136/jmg.37.9.695
149. Nisemblat, Y., Belinson, H., Dolev, I., and Michaelson, D. M. (2008). Activation of the amyloid cascade by intracerebroventricular injection of the protease inhibitor phosphoramidon. Neurodegener. Dis. 5, 166-169. doi: 10.1159/000113692
150. Niwa, K., Carlson, G. A., and Iadecola, C. (2000). Exogenous Aβ1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J. Cereb. Blood Flow Metab. 20, 1659-1668. doi: 10.1097/00004647-200012000-00005
151. Niwa, K., Kazama, K., Younkin, L., Younkin, S. G., Carlson, G. A., and Iadecola, C. (2002a). Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am. J. Physiol. Heart Circ. Physiol. 283, H315-H323. doi: 10.1152/ajpheart.00022.2002
152. Niwa, K., Kazama, K., Younkin, S. G., Carlson, G. A., and Iadecola, C. (2002b). Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis. 9, 61-68. doi: 10.1006/nbdi.2001.0460
153. Niwa, K., Porter, V. A., Kazama, K., Cornfield, D., Carlson, G. A., and Iadecola, C. (2001). A β-peptides enhance vasoconstriction in cerebral circulation. Am. J. Physiol. Heart Circ. Physiol. 281, H2417-H2424.
154. Oba, R., Igarashi, A., Kamata, M., Nagata, K., Takano, S., and Nakagawa, H. (2005). The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide. Eur. J. Neurosci. 21, 733-740. doi: 10.1111/j.1460-9568.2005.03912.x
155. O'Caoimh, R., Healy, L., Gao, Y., Svendrovski, A., Kerins, D. M., Eustace, J., et al. (2014). Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease. J. Alzheimers Dis. 40, 595-603. doi: 10.3233/JAD-131694
156. Ott, A., Breteler, M. M., de Bruyne, M. C., van Harskamp, F., Grobbee, D. E., and Hofman, A. (1997). Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 28, 316-321. doi: 10.1161/01.STR.28.2.316
157. Palmer, J., and Love, S. (2011). Endothelin receptor antagonists: potential in Alzheimer's disease. Pharmacol. Res. 63, 525-531. doi: 10.1016/j.phrs.2010.12.008
158. Palmer, J. C., Baig, S., Kehoe, P. G., and Love, S. (2009). Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Aβ. Am. J. Pathol. 175, 262-270. doi: 10.2353/ajpath.2009.081054
159. Palmer, J. C., Barker, R., Kehoe, P. G., and Love, S. (2012). Endothelin-1 is elevated in Alzheimer's disease and upregulated by amyloid-β. J. Alzheimers Dis. 29, 853-861. doi: 10.3233/JAD-2012-111760
160. Palmer, J. C., Kehoe, P. G., and Love, S. (2010). Endothelin-converting enzyme-1 in Alzheimer's disease and vascular dementia. Neuropathol. Appl. Neurobiol. 36, 487-497. doi: 10.1111/j.1365-2990.2010.01084.x
161. Palmer, J. C., Tayler, H. M., and Love, S. (2013). Endothelin-converting enzyme-1 activity, endothelin-1 production, and free radical-dependent vasoconstriction in Alzheimer's disease. J. Alzheimers Dis. 36, 577-587. doi: 10.3233/JAD-130383
162. Paris, D., Humphrey, J., Quadros, A., Patel, N., Crescentini, R., Crawford, F., et al. (2003). Vasoactive effects of A β in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. Neurol. Res. 25, 642-651. doi: 10.1179/016164103101201940
163. Park, L., Anrather, J., Forster, C., Kazama, K., Carlson, G. A., and Iadecola, C. (2004). Aβ-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex. J. Cereb. Blood Flow Metab. 24, 334-342. doi: 10.1097/01.WCB.0000105800.49957.1E
164. Pham, I., Uchida, T., Planes, C., Ware, L. B., Kaner, R., Matthay, M. A., et al. (2002). Hypoxia upregulates VEGF expression in alveolar epithelial cells in vitro and in vivo. Am. J. Physiol. Lung Cell. Mol. Physiol. 283, L1133-L1142. doi: 10.1152/ajplung.00464.2001
165. Poirier, R., Wolfer, D. P., Welzl, H., Tracy, J., Galsworthy, M. J., Nitsch, R. M., et al. (2006). Neuronal neprilysin overexpression is associated with attenuation of Aβ-related spatial memory deficit. Neurobiol. Dis. 24, 475-483. doi: 10.1016/j.nbd.2006.08.003
166. Powell, F. L. (2009). Adaptation to chronic hypoxia involves immune cell invasion and increased expression of inflammatory cytokines in rat carotid body. Am. J. Physiol. Lung Cell. Mol. Physiol. 296, L156-L157. doi: 10.1152/ajplung.90597.2008
167. Preston, S. D., Steart, P. V., Wilkinson, A., Nicoll, J. A., and Weller, R. O. (2003). Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid β from the human brain. Neuropathol. Appl. Neurobiol. 29, 106-117. doi: 10.1046/j.1365-2990.2003.00424.x
168. Price, D. L., Tanzi, R. E., Borchelt, D. R., and Sisodia, S. S. (1998). Alzheimer's disease: genetic studies and transgenic models. Annu. Rev. Genet. 32, 461-493. doi: 10.1146/annurev.genet.32.1.461
169. Revesz, T., Ghiso, J., Lashley, T., Plant, G., Rostagno, A., Frangione, B., et al. (2003). Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J. Neuropathol. Exp. Neurol. 62, 885-898.
170. Revesz, T., Holton, J. L., Lashley, T., Plant, G., Rostagno, A., Ghiso, J., et al. (2002). Sporadic and familial cerebral amyloid angiopathies. Brain Pathol. 12, 343-357. doi: 10.1111/j.1750-3639.2002.tb00449.x
171. Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., and Soubrier, F. (1990). An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86, 1343-1346. doi: 10.1172/JCI114844
172. Rossi, G. P., Sacchetto, A., Cesari, M., and Pessina, A. C. (1999). Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc. Res. 43, 300-307. doi: 10.1016/S0008-6363(99)00110-8
173. Rovelet-Lecrux, A., Hannequin, D., Raux, G., Le Meur, N., Laquerriere, A., Vital, A., et al. (2006). APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38, 24-26. doi: 10.1038/ng1718
174. Ruitenberg, A., den Heijer, T., Bakker, S. L., van Swieten, J. C., Koudstaal, P. J., Hofman, A., et al. (2005). Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann. Neurol. 57, 789-794. doi: 10.1002/ana.20493
175. Russo, R., Borghi, R., Markesbery, W., Tabaton, M., and Piccini, A. (2005). Neprylisin decreases uniformly in Alzheimer's disease and in normal aging. FEBS Lett. 579, 6027-6030. doi: 10.1016/j.febslet.2005.09.054
176. Saido, T. C. (2013). Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 89, 321-339. doi: 10.2183/pjab.89.321
177. Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., et al. (1996). Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2, 864-870. doi: 10.1038/nm0896-864
178. Schuff, N., Matsumoto, S., Kmiecik, J., Studholme, C., Du, A., Ezekiel, F., et al. (2009). Cerebral blood flow in ischemic vascular dementia and Alzheimer's disease, measured by arterial spin-labeling magnetic resonance imaging. Alzheimers Dement. 5, 454-462. doi: 10.1016/j.jalz.2009.04.1233
179. Selkoe, D. J. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
180. Sharp, P. F., Smith, F. W., Gemmell, H. G., Lyall, D., Evans, N. T., Gvozdanovic, D., et al. (1986). Technetium-99m HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies. J. Nucl. Med. 27, 171-177.
181. Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., et al. (2000). Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106, 1489-1499. doi: 10.1172/JCI10498
182. Shweiki, D., Neeman, M., Itin, A., and Keshet, E. (1995). Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 92, 768-772. doi: 10.1073/pnas.92.3.768
183. Spencer, B., Marr, R. A., Gindi, R., Potkar, R., Michael, S., Adame, A., et al. (2011). Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's disease. PLoS ONE 6:e16575. doi: 10.1371/journal.pone.0016575
184. Spencer, B., Marr, R. A., Rockenstein, E., Crews, L., Adame, A., Potkar, R., et al. (2008). Long-term neprilysin gene transfer is associated with reduced levels of intracellular Aβ and behavioral improvement in APP transgenic mice. BMC Neurosci. 9:109. doi: 10.1186/1471-2202-9-109
185. Stockley, J. H., Ravid, R., and O'Neill, C. (2006). Altered β-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer's disease brain. FEBS Lett. 580, 6550-6560. doi: 10.1016/j.febslet.2006.10.076
186. Sun, X., He, G., Qing, H., Zhou, W., Dobie, F., Cai, F., et al. (2006). Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc. Natl. Acad. Sci. U.S.A. 103, 18727-18732. doi: 10.1073/pnas.0606298103
187. Sun, X., Wiesner, B., Lorenz, D., Papsdorf, G., Pankow, K., Wang, P., et al. (2008). Interaction of angiotensin-converting enzyme (ACE) with membrane-bound carboxypeptidase M (CPM) - a new function of ACE. Biol. Chem. 389, 1477-1485. doi: 10.1515/BC.2008.168
188. Sun, Y., Jin, K., Mao, X. O., Zhu, Y., and Greenberg, D. A. (2001). Neuroglobin is up-regulated by and protects neurons from hypoxic-ischemic injury. Proc. Natl. Acad. Sci. U.S.A. 98, 15306-15311. doi: 10.1073/pnas.251466698
189. Sundelof, J., Sundstrom, J., Hansson, O., Eriksdotter-Jonhagen, M., Giedraitis, V., Larsson, A., et al. (2010). Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls. J. Alzheimers Dis. 22, 1223-1230. doi: 10.3233/JAD-2010-101023
190. Takanashi, M., Miyauchi, T., Kakinuma, Y., Goto, K., and Yamaguchi, I. (2004). Establishment of hypoxia inducible factor-1α overexpressing cells that produce endothelin-1. J. Cardiovasc. Pharmacol. 44(Suppl. 1), S268-S273. doi: 10.1097/01.fjc.0000166282.01034.8f
191. Tanzi, R. E., and Bertram, L. (2005). Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120, 545-555. doi: 10.1016/j.cell.2005.02.008
192. Terao, C., Bayoumi, N., McKenzie, C. A., Zelenika, D., Muro, S., Mishima, M., et al. (2013). Quantitative variation in plasma angiotensin-I converting enzyme activity shows allelic heterogeneity in the ABO blood group locus. Ann. Hum. Genet. 77, 465-471. doi: 10.1111/ahg.12034
193. Thornton-Wells, T. A., Moore, J. H., Martin, E. R., Pericak-Vance, M. A., and Haines, J. L. (2008). Confronting complexity in late-onset Alzheimer disease: application of two-stage analysis approach addressing heterogeneity and epistasis. Genet. Epidemiol. 32, 187-203. doi: 10.1002/gepi.20294
194. Tian, M., Zhu, D., Xie, W., and Shi, J. (2012). Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains. FEBS Lett. 586, 3737-3745. doi: 10.1016/j.febslet.2012.09.004
195. Tong, X. K., Nicolakakis, N., Kocharyan, A., and Hamel, E. (2005). Vascular remodeling versus amyloid β-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. J. Neurosci. 25, 11165-11174. doi: 10.1523/JNEUROSCI.4031-05.2005
196. Toropygin, I. Y., Kugaevskaya, E. V., Mirgorodskaya, O. A., Elisseeva, Y. E., Kozmin, Y. P., Popov, I. A., et al. (2008). The N-domain of angiotensin-converting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer's Aβ-(1-16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 22, 231-239. doi: 10.1002/rcm.3357
197. Tucker, H. M., Kihiko, M., Caldwell, J. N., Wright, S., Kawarabayashi, T., Price, D., et al. (2000). The plasmin system is induced by and degrades amyloid-β aggregates. J. Neurosci. 20, 3937-3946.
198. Turner, A. J., and Hooper, N. M. (2002). The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol. Sci. 23, 177-183. doi: 10.1016/S0165-6147(00)01994-5
199. Tyler, S. J., Dawbarn, D., Wilcock, G. K., and Allen, S. J. (2002). α- and β-secretase: profound changes in Alzheimer's disease. Biochem. Biophys. Res. Commun. 299, 373-376. doi: 10.1016/S0006-291X(02)02635-9
200. van Dorpe, J., Smeijers, L., Dewachter, I., Nuyens, D., Spittaels, K., Van Den Haute, C., et al. (2000). Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am. J. Pathol. 157, 1283-1298. doi: 10.1016/S0002-9440(10)64644-5
201. Vogelgesang, S., Cascorbi, I., Schroeder, E., Pahnke, J., Kroemer, H. K., Siegmund, W., et al. (2002). Deposition of Alzheimer's β-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12, 535-541. doi: 10.1097/00008571-200210000-00005
202. Walker, J. R., Pacoma, R., Watson, J., Ou, W., Alves, J., Mason, D. E., et al. (2013). Enhanced proteolytic clearance of plasma Aβ by peripherally administered neprilysin does not result in reduced levels of brain Aβ in mice. J. Neurosci. 33, 2457-2464. doi: 10.1523/JNEUROSCI.3407-12.2013
203. Wang, D. S., Dickson, D. W., and Malter, J. S. (2006). β-Amyloid degradation and Alzheimer's disease. J. Biomed. Biotechnol. 2006:58406. doi: 10.1155/JBB/2006/58406
204. Wang, J., Ho, L., Chen, L., Zhao, Z., Zhao, W., Qian, X., et al. (2007). Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J. Clin. Invest. 117, 3393-3402. doi: 10.1172/JCI31547
205. Wang, R., Wang, S., Malter, J. S., and Wang, D. S. (2009a). Effects of HNE-modification induced by Aβ on neprilysin expression and activity in SH-SY5Y cells. J. Neurochem. 108, 1072-1082. doi: 10.1111/j.1471-4159.2008.05855.x
206. Wang, R., Wang, S., Malter, J. S., and Wang, D. S. (2009b). Effects of 4-hydroxy-nonenal and Amyloid-β on expression and activity of endothelin converting enzyme and insulin degrading enzyme in SH-SY5Y cells. J. Alzheimers Dis. 17, 489-501. doi: 10.3233/JAD-2009-1066
207. Weller, R. O., Boche, D., and Nicoll, J. A. (2009b). Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol. 118, 87-102. doi: 10.1007/s00401-009-0498-z
208. Weller, R. O., Massey, A., Kuo, Y. M., and Roher, A. E. (2000). Cerebral amyloid angiopathy: accumulation of A β in interstitial fluid drainage pathways in Alzheimer's disease. Ann. N.Y. Acad. Sci. 903, 110-117. doi: 10.1111/j.1749-6632.2000.tb06356.x
209. Weller, R. O., Massey, A., Newman, T. A., Hutchings, M., Kuo, Y. M., and Roher, A. E. (1998). Cerebral amyloid angiopathy: amyloid β accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am. J. Pathol. 153, 725-733. doi: 10.1016/S0002-9440(10)65616-7
210. Weller, R. O., Preston, S. D., Subash, M., and Carare, R. O. (2009a). Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res. Ther. 1, 6. doi: 10.1186/alzrt6
211. Wenger, R. H. (2002). Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J. 16, 1151-1162. doi: 10.1096/fj.01-0944rev
212. Wosik, K., Cayrol, R., Dodelet-Devillers, A., Berthelet, F., Bernard, M., Moumdjian, R., et al. (2007). Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J. Neurosci. 27, 9032-9042. doi: 10.1523/JNEUROSCI.2088-07.2007
213. Yamashita, K., Discher, D. J., Hu, J., Bishopric, N. H., and Webster, K. A. (2001). Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, AND p300/CBP. J. Biol. Chem. 276, 12645-12653. doi: 10.1074/jbc.M011344200
214. Yamin, R., Zhao, C., O'Connor, P. B., McKee, A. C., and Abraham, C. R. (2009). Acyl peptide hydrolase degrades monomeric and oligomeric amyloid-β peptide. Mol. Neurodegener. 4, 33. doi: 10.1186/1750-1326-4-33
215. Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., et al. (2006). Matrix metalloproteinase-9 degrades amyloid-β fibrils in vitro and compact plaques in situ. J. Biol. Chem. 281, 24566-24574. doi: 10.1074/jbc.M602440200
216. Yanagisawa, H., Hammer, R. E., Richardson, J. A., Emoto, N., Williams, S. C., Takeda, S., et al. (2000). Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J. Clin. Invest. 105, 1373-1382. doi: 10.1172/JCI7447
217. Yanagisawa, M., Kurihara, H., Kimura, S., Goto, K., and Masaki, T. (1988). A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J. Hypertens. Suppl. 6, S188-S191. doi: 10.1097/00004872-198812040-00056
218. Yasojima, K., Akiyama, H., McGeer, E. G., and McGeer, P. L. (2001). Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of β-amyloid peptide. Neurosci. Lett. 297, 97-100. doi: 10.1016/S0304-3940(00)01675-X
219. Yin, K. J., Cirrito, J. R., Yan, P., Hu, X., Xiao, Q., Pan, X., et al. (2006). Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-β peptide catabolism. J. Neurosci. 26, 10939-10948. doi: 10.1523/JNEUROSCI.2085-06.2006
220. Zetterberg, H., Mortberg, E., Song, L., Chang, L., Provuncher, G. K., Patel, P. P., et al. (2011). Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid β levels in humans. PLoS ONE 6:e28263. doi: 10.1371/journal.pone.0028263
221. Zhang, X., Zhou, K., Wang, R., Cui, J., Lipton, S. A., Liao, F. F., et al. (2007). Hypoxia-inducible factor 1α (HIF-1α)-mediated hypoxia increases BACE1 expression and β-amyloid generation. J. Biol. Chem. 282, 10873-10880. doi: 10.1074/jbc.M608856200
222. Zhao, J., Fu, Y., Yasvoina, M., Shao, P., Hitt, B., O'Connor, T., et al. (2007). B-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J. Neurosci. 27, 3639-3649. doi: 10.1523/JNEUROSCI.4396-06.2007
223. Zheng, W. H., Bastianetto, S., Mennicken, F., Ma, W., and Kar, S. (2002). Amyloid β peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience 115, 201-211. doi: 10.1016/S0306-4522(02)00404-9
224. Zhiyou, C., Yong, Y., Shanquan, S., Jun, Z., Liangguo, H., Ling, Y., et al. (2009). Upregulation of BACE1 and β-amyloid protein mediated by chronic cerebral hypoperfusion contributes to cognitive impairment and pathogenesis of Alzheimer's disease. Neurochem. Res. 34, 1226-1235. doi: 10.1007/s11064-008-9899-y
225. Zhu, D., Shi, J., Zhang, Y., Wang, B., Liu, W., Chen, Z., et al. (2011). Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats. PLoS ONE 6:e16037. doi: 10.1371/journal.pone.0016037
226. Zou, K., Yamaguchi, H., Akatsu, H., Sakamoto, T., Ko, M., Mizoguchi, K., et al. (2007). Angiotensin-converting enzyme converts amyloid β-protein 1-42 (Aβ(1-42)) to Aβ(1-40), and its inhibition enhances brain Aβ deposition. J. Neurosci. 27, 8628-8635. doi: 10.1523/JNEUROSCI.1549-07.2007